In summary, our data reveal an unexpected regulatory mechanism in which SUMOylation increases the ability of NDRG2 to inhibit lung cancer tumorigenesis, and RNF4 targets NDRG2 to proteasomal degradation by stimulating its SUMOylation. Here, RNF4 is linked to lung cancer.